Drugs / Allogeneic Human Cardiosphere-Derived Stem Cells
Allogeneic Human Cardiosphere-Derived Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03145298 | Oct 2017 → Jan 2023 | pulmonary arterial hypertension | Cedars-Sinai Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Human Cardiosphere-Derived Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03145298 ↗ |
| Modality | Cell therapy | “Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue” NCT03145298 ↗ |